{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-22-000122","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.693144+00:00","generated_at":"2026-06-26T00:08:53.622635+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Artivion Q1 revenue up 8.6% to $77.2M; net loss of $0.08 per share","bullets":["Revenue $77.2M, +8.6% GAAP YoY; constant currency growth 11.2% driven by aortic stent grafts (+34%) and On-X (+11%).","Net loss $3.4M ($0.08/share) vs $3.1M loss in Q1 2021; non-GAAP net income $1.1M ($0.03/share) vs $1.4M.","Asia Pacific constant currency revenue +39%; Latin America +93%. Pipeline progress: PROACT Mitral and PerClot FDA PMA expected in 2022.","FY 2022 constant currency revenue growth guidance reaffirmed at 9.0%-11.0%."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-22-000122","json":"https://secwatch.observer/filing/0000784199-22-000122.json","markdown":"https://secwatch.observer/filing/0000784199-22-000122.md","text":"https://secwatch.observer/filing/0000784199-22-000122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419922000122/0000784199-22-000122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419922000122/aort-20220505x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:08:53.622635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}